Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Undervalued wide moat share may be overlooked
A series of negative updates dulls sentiment in wide moat share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,160.30 | 13.70 | -0.15% |
| CAC 40 | 8,244.29 | 57.56 | -0.69% |
| DAX 40 | 25,745.35 | 224.76 | -0.87% |
| Dow JONES (US) | 52,766.88 | 419.02 | -0.79% |
| FTSE 100 | 10,720.61 | 68.67 | -0.64% |
| HKSE | 25,311.21 | 18.52 | -0.07% |
| NASDAQ | 26,099.77 | 271.12 | -1.03% |
| Nikkei 225 | 64,325.64 | 1,889.70 | -2.85% |
| NZX 50 Index | 13,930.57 | 143.67 | 1.04% |
| S&P 500 | 7,631.47 | 54.67 | -0.71% |
| S&P/ASX 200 | 8,978.40 | 1.80 | -0.02% |
| SSE Composite Index | 3,941.39 | 38.50 | -0.97% |